T he ability of combination antiretroviral therapy (cART) to suppress replication of the Human Immunodeficiency Virus (HIV) has provided enormous clinical and survival benefits to HIV-infected persons. [1] [2] [3] [4] Unfortunately, not all patients derive this benefit. Although the dosing frequency and side effects of cART have improved since the introduction of cART in the mid-1990s, adherence to treatment regimen remains a challenge for many HIV-infected patients and is a principal reason for failure to suppress viral replication, emergence of antiretroviral resistance, and disease progression. [5] [6] [7] [8] [9] Poor medication adherence in HIV-infected patients is related to the complexity of the treatment regimen, medication side effects, patient beliefs in the effectiveness of treatment, and access to medical care. 10, 11 In addition, comorbidities such as substance abuse disorders, mental health disorders, hepatitis C infection, diabetes, and heart disease, which are common in HIV-infected patients, complicate treatment plans and are associated with lower adherence to cART. [12] [13] [14] [15] [16] [17] [18] The consequences of poor adherence to antiretroviral therapy have led to the development of multiple patientcentered interventions to modify patient behavior such as providing pagers to remind patient to take their medications or education regarding the importance of adherence and management of side effect profiles. 19, 20 Although these interventions are important, relatively less attention has been paid to addressing comorbidities to improve adherence and consequent viral suppression. The most common way that HIV clinics address comorbidities is by integrating noninfectious disease providers such as psychiatrists and social workers into HIV primary care. Various degrees of such integration have been implemented in portions of the Department of Veterans Affairs (VA) healthcare system as well as other healthcare systems in the United States. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] In their most developed form, these VA clinics provide on-site pharmacy services, mental health care, urgent care, substance abuse treatment, women's healthcare, and case management. 30 Formal analyses that evaluate the benefit of such programs are lacking, however. 31 To better understand the relationship of Integrated HIV Care (IHC) to patient health outcomes, we conducted a retrospective cohort study to evaluate the association of patient utilization of IHC with the likelihood of achieving viral suppression among HIV-infected patients receiving care at 5 VA healthcare facilities in Southern California and Nevada.
METHODS

Conceptual Model
We defined IHC to be a care model in which specialists from multiple disciplines collaborate within a geographically and temporally constrained clinic environment to provide HIV-infected patients with onsite primary care, HIV specialty services, and other services such as treatment for hepatitis C, mental health, substance abuse, social services, etc. We adopted the Donabedian model 32 to examine the impact of IHC on viral suppression among HIV-infected patients. In this conceptual model, IHC (ie, structure) influences the way in which providers manage patients' comorbidities and encourage patients to adhere to medications (ie, process), hence influencing viral suppression (ie, outcomes). We hypothesized that IHC enables providers within multidisciplinary teams to manage comorbidities more effectively and promote better adherence to antiretroviral medication regimens; as a result, patients with comorbidities who used IHC more frequently would be more likely to achieve suppression of HIV replication.
Study Design
We conducted a retrospective cohort study of HIVinfected patients receiving care from 5 Veterans Affairs healthcare facilities in the Western United States from October 2000 to April 2006. We interviewed the chiefs of the HIV clinics at these facilities to measure and rank levels of IHC at their clinics. These rankings were applied to patient visits obtained from electronic medical records to form an index of IHC utilization. Using survival analysis, we analyzed the effect of IHC utilization on the likelihood of achieving viral suppression while on cART, controlling for demographic and clinical factors.
Data Sources
We obtained administrative and clinical data of inpatient and outpatient encounters from a VA regional electronic data warehouse. The data were longitudinal and comprehensive, including, patient demographics, date and time of health service, type of provider, location of service, laboratory tests and results, pharmacy prescriptions and refills, purpose of visit or reason for admission (diagnostic codes), and service provided (surgical and procedure codes). In addition to using these electronic medical data, we interviewed the chiefs of the Infectious Disease clinics at the 5 VA facilities to obtain the descriptions of integrated services that comprised their HIV clinics.
Inclusion Criteria
An HIV-infected patient had to have a viral load Ն5000 at study entry, at least 2 HIV clinic visits per year, and at least a 3-month supply of cART during the observation period.
Patients who met these criteria were included in the analysis regardless of whether they achieved viral suppression or not. cART was determined by synchronous receipt of 2 nucleoside/nucleotide analogues and at least 1 protease inhibitor, non-nucleoside reverse transcription inhibitor, or fusion inhibitor. Patients were identified as being HIV-infected if they had qualified under any of the following criteria: 2 or more outpatient visits with a recorded diagnosis of HIV infection, one or more inpatient stays with a diagnosis of HIV infection, 33 
Statistical Methods
To assess the effect of IHC utilization on time to viral suppression adjusted for patient demographic and clinical characteristics, we used survival analysis with the Cox regression method in which the hazard function was determined by the rates at which patients achieved viral suppression over time. The dependent variable was the time from cART initiation to the first achievement of viral suppression. Although the study span was 2000 to 2006, each patient had their own observation period starting from the entry date when they started cART after their viral load was first recorded as being Ն5000 HIV-1 RNA copies/mL to the date when they achieved viral suppression below 400 copies/mL. Patients who had not achieved viral suppression by the end of the study period (ie, loss to follow-up) were assigned a "right-censored" time counting from study entry to their last visit. The independent variables included patient age, race and ethnicity, marital status, copayment for VA medical costs as a proxy for income, lack of housing, sexually transmitted diseases, comorbidities, baseline HIV viral load and CD4 ϩ cell count, treatment-naive versus treatment-experienced, access to cART medication as determined by pharmacy data, and utilization of IHC as determined by clinic visits. Baseline CD4 ϩ cell counts and viral loads were based on the first laboratory tests taken upon patient entry into the study. All viral load values were log 10 -transformed. Access to cART medication was computed by refill frequency during the observation period. 34 Appendix 1 (Supplemental Digital Content 1, http://links.lww.com/A893) provides details of the diagnostic codes and laboratory tests used to determine the comorbidities. Patients were considered as treatment-naive if they had an HIV-positive antibody test and a subsequent viral load Ն5000 at study entry, followed by the first cART prescription. Patients were considered as treatment-experienced if they had records of receipt of cART before study entry. For those patients whose HIV status was determined by ICD-9 codes or positive viral loads and who initiated cART after study entry but did not have record of positive HIV antibody tests, we could not determine whether they were treatment-naive or treatment-experienced; therefore we assigned such patients an unknown status.
To measure patient utilization of IHC, we first ranked the comprehensive level of IHC of the HIV clinics. We classified these clinics into 4 levels of comprehensiveness based on the number of services and the amount of resources devoted to each service (Table 1) . Level I clinics offered walk-in services provided by a midlevel provider only (ie, a nurse practitioner or physician assistant). Level II clinics offered more comprehensive care than Level I with the presence of an HIV physician specialist and a dedicated pharmacist. In addition to all services available in Level II clinics, Level III clinics offered psychiatric and social services. Level IV clinics offered the most comprehensive care with the addition of a psychologist. Various study facilities offered different IHC clinics on different days of the week at different locations. For example, facility E offered Level IV clinic on Tuesday afternoons, Level III clinic on Monday and Wednesday mornings, Level II clinic on Friday mornings, and Level I (walk-in) clinic on the other times of the week.
The distribution of IHC users across the 5 VA facilities is shown in Table 2 .
Since more than half of the patients visited multiple IHC clinics, we evaluated their utilization of IHC by the following index:
Today days of observation * 90
In this index, the total days of observation referred to the number of days between study entry and viral suppression or loss to follow-up. We quantified the 4 IHC levels as 1, 2, 3, and 4. The index gave each patient a score that weighed the frequency of HIV clinic visits by these IHC levels. Patients who visited clinics of higher IHC level were assigned higher scores. Thus a patient with 1 visit to a Level IV clinic every 90 days would receive a score of 4 as would a patient with 2 visits to a Level II clinic during the same period. We conducted 2 survival analyses. In the first analysis, we included all study patients and evaluated the effect of IHC utilization index on time to viral suppression, adjusted for the demographic and clinical variables mentioned above. The second analysis was similar to the first one except that we included the subset of patients who visited only 1 IHC level and that we replaced the IHC utilization index by the categorical variable indicating the levels of the IHC clinics and the number of visits to the clinics per quarter. In both analyses, the effects were assessed by adjusted hazard ratios. Similar to the interpretation of risk ratios, hazard ratio values of less than 1 indicated negative association (ie, less likely to achieve viral suppression) whereas a value greater than 1 indicated positive association (ie, more likely to achieve viral suppression), and a value equal to 1 indicated no association (ie, no change in likelihood of viral suppression). Since patients who received care at the same facilities might experience similar health outcomes, we adjusted the regression model for intrafacility clustering. Finally, we conducted a sensitivity analysis to examine how choices of baseline viral load threshold other than 5000 counts would affect the study results. All statistical analyses were programmed in SAS 35 and STATA. 36 
RESULTS
A total of 2883 patients were identified as being HIVinfected. Of these, 1018 (35.3%) patients met the inclusion criteria. Table 3 presents the baseline demographic and clinical characteristics of the study patients. Overall, the patients had substantial potential barriers to responding to antiretroviral therapy. Approximately 18% of the patients had a history of homelessness; 93% had one or more comorbid conditions with a mean of 3.2 comorbidities per patient (SD ϭ 2.0). The most prevalent comorbidities were mental disorders (55.5%), prior or current hepatitis B infection (48.8%), hepatitis C infection (33.1%), and illicit drug or alcohol use (31.4%). Analysis of prior treatment indicated that 497 (48.8%) patients were treatment-experienced whereas 187 (18.4%) patients were treatment-naive. We could not determine whether the remaining 334 (32.8%) patients were treatment experienced or naive because of insufficient information. Comparing users of the 4 IHC levels, we found that the 4 groups were different in their compositions of race/ethnicity, homelessness, baseline HIV viral load, and CD4 ϩ cell counts (all P Ͻ 0.01). For example, users of Level III had the lowest baseline HIV viral loads, whereas users of Level I were most likely to be homeless. Despite these differences, all 4 groups were similar in comorbidity prevalence, access to cART, and frequency of visits to HIV clinics. These similarities indicate that the need for IHC was comparable among the 4 groups.
We used Kaplan-Meier method to estimate the cumulative probability of viral suppression among patients who accessed only 1 IHC level. Figure 1 shows the Kaplan-Meier curves depicting the cumulative probability of viral suppression stratified by IHC levels. The plot shows that by the 9th month (ie, 270th day) of cART, Level IV users had 60% probability of viral suppression, whereas Level I, Level II, and Level III users all had 32% probability of viral suppression. By the 27th month (ie, 810th day) of cART, Level IV users had 80% probability of viral suppression; Level III users had 60% probability; and Level I and Level II users both had 53% probability. By the end of the study, the probability of viral suppression was 95% for Level IV users, 87% for Level III users, 83% for Level II users, and 60% for Level I users. All comparative differences were statistically significant at P Ͻ 0.01. In summary, the higher the IHC level, the higher the cumulative probability of viral suppression.
In subsequent analyses, we adjusted for the demographic and clinical differences among the 4 groups when assessing the effect of IHC levels on time to viral suppression. Table 4 shows the adjusted hazard ratios obtained from 2 survival analyses, the first involving all study patients (n ϭ 1018) and the second involving the subset of patients who accessed only 1 level of IHC clinics (n ϭ 514). From the first analysis, we found that once-married patients and those with high income were more likely to achieve viral suppression than those who were never married ͓hazard ratio (HR) ϭ 1.34, confidence interval (CI) ϭ 1.21-1.50͔ and had low income (HR ϭ 1.14, CI ϭ 1.01-1.30). Conversely, homeless patients were less likely to achieve viral suppression (HR ϭ 0.78, CI ϭ 0.67-0.90). Patients who had higher baseline CD4 ϩ cell counts were more likely to achieve viral suppression (HR ϭ 1.06, CI ϭ 1.05-1.08). Most importantly, patients who had more access to cART were much more likely to achieve viral suppression (HR ϭ 3.13, CI ϭ 2. 22-4.40) . In analyses that controlled for these demographic and clinical factors, patients who had a higher index of IHC utilization were more likely to achieve viral suppression (HR ϭ 1.10, CI ϭ 1.09 -1.11). From the second analysis, we found that there was no difference in viral suppression between patients who visited clinics of Level I and Level II. However, patients who visited clinics of Level III and Level IV were 1.7 times and 3.1 times more likely to achieve viral suppression than those who visited clinics of Level II (Level III: HR ϭ 1.74, CI ϭ 1.06 -2.85. Level IV: HR ϭ 3.10, CI ϭ 1.76 -5.47). Regardless of IHC levels, patients who visited clinics more frequently were more likely to achieve viral suppression (HR ϭ 1.42, CI ϭ 1.32-1.53).
Sensitivity Analysis
We examined the sensitivity of our results to the choice of baseline viral load. We repeated the survival analysis with baseline viral load values varying between 1000 and 10,000 counts (instead of 5000). Regardless of the viral load choices, the results were consistent.
DISCUSSION
We evaluated the virological response to cART in 1018 HIV-infected veterans who received care at 5 VA healthcare facilities. We found that patients who visited HIV clinics with more integrated specialty services were more likely to achieve viral suppression. In particular, patients visiting clinics which offered hepatitis, psychiatric, psychologic, and social services in addition to primary care and HIV specialty services were 3 times more likely to achieve viral suppression than patients visiting clinics which offered only primary care and HIV specialty services. This effect had been adjusted for patients' access to antiretroviral medication and demographic and clinical factors.
We believe that our results are generalizable to care settings beyond the VA. VA HIV-infected patients are older and have more comorbidities than generally reported. [37] [38] [39] However, with the improved outcomes being seen with HIV treatment, the HIV-infected patient population is generally aging and becoming more susceptible to comorbidities, and the VA population may represent the future of the US HIV epidemic in that respect. 40 -42 Except for being overwhelmingly male, the income status and racial/ethnic distribution of HIV-infected veterans is similar to that of many other HIVinfected populations in the US. The median time to viral suppression of our study patients is longer than that reported in modern clinical trials of treatment-naive patients, reflecting the fact that majority of our study patients experienced multiple comorbid conditions and prior failures to respond to treatment.
The principal limitation of our study is that unmeasured differences between the patients seen at the differing clinics and unmeasured differences in the skills of the providers who staff those clinics, rather than the comprehensiveness of care, may have accounted for our findings. 43, 44 However, we note that our statistical models have corrected for patient demographic and clinical factors that are previously reported to modulate the effectiveness of antiretroviral therapy. In addition, provider surveys indicate that the distribution of physician experience and expertise in the management of HIV infection is similar among persons staffing the Level II, Level III, and Level IV clinics. Indeed, in many instances the same physicians provide services in more than one type of clinic. Another limitation is that we did not explicitly compare the potency of antiretroviral therapy (eg, the use of ritonavirboosted protease inhibitors, triple nucleoside therapy, or hard-gel saquinavir) in the patient population 2, 6 or the complexity of antiretroviral therapy (ie, doses per day, pills per day, or dietary restrictions). However, the availability of laboratory and pharmacy records monitoring patient viral loads and access to antiretroviral medications is the same at all clinic levels; as is the policy to provide care as recommended by national guidelines. 6, 45 Although we accounted for treatment-experienced status in the analysis, we could not account for the unmeasured duration of cART before study entry, which might be associated with viral suppression. The limitations of our statistical analysis are that the quantification of the 4 IHC levels in the IHC utilization index was arbitrary, and that the retrospective nature of this study limited our ability to consider whether temporal changes in clinic structure and operations might have impacted our results.
This study made use of the electronic medical records maintained by the Veterans Health Administration. 46, 47 Because HIV-infected veterans who are VA heath care users receive over 70% of their total care and obtain 98% of their prescriptions through the VA, 37 these records allowed us to access nearly complete records of patient demographics, receipt of antiretroviral prescriptions, clinic visits, relevant laboratory results, and medical comorbidities such as hepatitis B and C, mental illnesses, drug or alcohol use, STDs, diabetes, heart disease, COPD, tuberculosis, cirrhosis, stroke, and cancer. However, the VA electronic database had several limitations such as high rates of missing race data and diagnostic coding errors which could affect the quality of the present data analysis. 48, 49 Literature shows that comorbid conditions such as alcohol abuse, substance use, and mental health disorders, all of which impede patient adherence to cART, [13] [14] [15] 18 are highly prevalent in HIV-infected patients. 41 The Veteran Affairs Healthcare system has implemented IHC in which subspecialty programs are integrated into HIV clinics to address comorbid conditions and medication adherence. However, our study is one of the few to evaluate the relationship between the level of services provided by an IHC clinic and patient health outcomes. 31 We believe that IHC clinics at the VA facilities may have effectively addressed comorbidities and encouraged medication adherence. Based on our finding that frequency of visits was a strong predictor for viral suppression, we suggest not only that resources should be allocated to integrate subspecialty services into HIV primary care clinics but also that providers should channel patients toward these clinics and retain them in care. Future studies should examine which specific elements of IHC are most associated with viral control and what role provider experience plays in this association. Finally, these results may be relevant not only to the care of HIV-infected patients but also to the provision of care of patients with other complex medical issues that require principal care in subspecialty clinics.
